<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02565511</url>
  </required_header>
  <id_info>
    <org_study_id>CAPI015A2201J</org_study_id>
    <secondary_id>2015-002715-15</secondary_id>
    <secondary_id>1UF1AG046150-01</secondary_id>
    <nct_id>NCT02565511</nct_id>
  </id_info>
  <brief_title>A Study of CAD106 and CNP520 Versus Placebo in Participants at Risk for the Onset of Clinical Symptoms of Alzheimer's Disease</brief_title>
  <acronym>Generation S1</acronym>
  <official_title>A Randomized, Double-blind, Placebo-controlled, Two-cohort, Parallel Group Study to Evaluate the Efficacy of CAD106 and CNP520 in Participants at Risk for the Onset of Clinical Symptoms of Alzheimer's Disease.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Banner Alzheimer's Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institute on Aging (NIA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Alzheimer's Association</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Amgen</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to test whether two investigational drugs called CAD106 and
      CNP520, administered separately, can slow down the onset and progression of clinical symptoms
      associated with Alzheimer's disease (AD) in participants at the risk to develop clinical
      symptoms based on their age and genotype.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will assess the effects of each of the two therapies given separately, both
      targeting amyloid, on cognition, global clinical status, and underlying pathology in
      participants at risk for the onset of clinical symptoms of Alzheimer's disease (AD).
      Cognitively unimpaired individuals with two APOE4 genes and age 60 to 75 years, inclusive,
      are selected as they represent a population at particularly high risk of progression to Mild
      Cognitive Impairment and/or dementia due to Alzheimer's disease.

      The study follows a randomized, double-blind, placebo-controlled, two-cohort, parallel group
      design in which participants receive one of the investigational treatments or their matching
      placebo for at least 60 months up to a maximum of 96 months and no longer than when the
      target number of events for the TTE endpoint has been observed and confirmed in either
      cohort.

      An unbalanced randomization (active: placebo) of 5:3 ratio in Cohort I (430 CAD106 :260
      Placebo) and 3:2 ratio in Cohort II (390 CNP520 : 260 Placebo) will be applied. Randomization
      will be stratified by age group (60-64 years, 65-75 years) and region (North America/Other ,
      Europe).

      Participants who meet study entry requirements will be required to undergo at least two PET
      scans during the course of the study. Additional PET scans, blood and CSF collection will be
      voluntary. The study (also known as the Generation Study 1) is conducted as part of the
      Alzheimer's Prevention Initiative (API) program.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 30, 2015</start_date>
  <completion_date type="Anticipated">September 2, 2024</completion_date>
  <primary_completion_date type="Anticipated">August 30, 2024</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to diagnosis of MCI due to Alzheimer's Disease (AD) or dementia due to Alzheimer's Disease</measure>
    <time_frame>Through study completion, an average of 5 years</time_frame>
    <description>Time when diagnosis is confirmed by adjudication committee</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in the Alzheimer's Prevention Initiative Composite Cognitive (APCC) Test Score</measure>
    <time_frame>Baseline to Month 60</time_frame>
    <description>Composite score derived from the specific tests from the Repeatable Battery for the Assessment of Neurological Status (RBANS), Mini-Mental State Examination (MMSE), Raven's Progressive Matrices</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Clinical Dementia Rating Scale Sum of Boxes (CDR-SOB) score</measure>
    <time_frame>Baseline to Month 60</time_frame>
    <description>To assess the effects of CAD106 and CNP520, vs. respective placebo on global clinical status as measured by the change in Clinical Dementia Rating Scale Sum of Boxes (CDR-SOB) score.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with Adverse Events as a measure of Safety and Tolerability</measure>
    <time_frame>Through study completion, an average of 5 years</time_frame>
    <description>To assess the safety and tolerability of CAD106 and CNP520, vs. respective placebo by measured adverse events (AEs), and changes in the brain structural MRI, laboratory tests, non-cognitive neurological and psychiatric examinations including the Columbia Suicide Severity Rating Scale (C-SSRS), vital signs and electrocardiogram (ECG).
Cohort - I: Injection-related reactions will also be analyzed. Cohort - II: Skin related AEs by regular skin examinations and centralized dermatological monitoring.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change on the Total Scale score and individual neurocognitive domain index scores of the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS)</measure>
    <time_frame>Baseline to Month 60</time_frame>
    <description>To assess the effects of CAD106 and CNP520, vs. respective placebo on cognition as measured by changes on the Total Scale score and individual neurocognitive domain index scores of the RBANS.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in the Everyday Cognition scale (ECog) total scores</measure>
    <time_frame>Baseline to Month 60</time_frame>
    <description>To assess the effects of CAD106 and CNP520, vs. respective placebo on function as measured by the change in ECog total score reported by the participant and study partner, respectively.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Alzheimer's Disease related biomarkers</measure>
    <time_frame>Baseline to Months 24 and 60</time_frame>
    <description>To assess the effects of CAD106 and CNP520, vs. respective placebo on AD-related biomarkers (amyloid deposition and measures of neurodegeneration) as measured by changes on:
amyloid tracer and tau tracer obtained using brain positron emission tomography (PET) imaging, volumetric MRI measurements, and CSF Aβ40, Aβ42, total tau and phosphorylated tau181 levels.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in APCC Test Score</measure>
    <time_frame>Month 6 to Month 60</time_frame>
    <description>To assess the effects of antibody response to CAD106 vs. placebo on cognition as measured by changes on the APCC test score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in CDR-SOB</measure>
    <time_frame>Month 6 to Month 60</time_frame>
    <description>To assess the effects of antibody response to CAD106 vs. placebo on cognition as measured by changes on the CDR-SOB.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Aβ-specific immune response</measure>
    <time_frame>Through study completion, an average of 5 years</time_frame>
    <description>To describe serological immune response to CAD106 injections as measured by Aβ-specific antibody titers generated</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">1340</enrollment>
  <condition>Alzheimer's Disease</condition>
  <arm_group>
    <arm_group_label>Arm#1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CAD106 (450 µg) + Alum (450 µg) given i.m. at week 1, 7, 13 and quarterly thereafter</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm#2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo to CAD106 + Alum (450 µg) given i.m. at week 1, 7, 13 and quarterly thereafter</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm#3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CNP520 (50 mg) capsules oral intake (p.o.)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm#4</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo to CNP520 capsules oral intake (p.o.)</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>CAD106 Immunotherapy</intervention_name>
    <description>Participants will be given i.m. injections at Weeks 1, 7, 13 and quarterly i.m. injections (every 13 weeks) thereafter, until the last injection 3 month prior to completion of the Treatment Epoch.</description>
    <arm_group_label>Arm#1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo to CAD106</intervention_name>
    <description>Participants will be given i.m. injections at Weeks 1, 7, 13 and quarterly i.m. injections (every 13 weeks) thereafter, until the last injection 3 month prior to completion of the Treatment Epoch.</description>
    <arm_group_label>Arm#2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CNP520</intervention_name>
    <description>CNP520 50 mg capsule p.o. for the duration of the Treatment Epoch.</description>
    <arm_group_label>Arm#3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo to CNP520</intervention_name>
    <description>Placebo to CNP520 p.o. for the duration of the Treatment Epoch</description>
    <arm_group_label>Arm#4</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Consent to receive disclosure of their risk estimates to develop clinical symptoms of
             AD based on their APOE genotype.

          -  Male or female, age 60 to 75 years inclusive. Females must be considered
             post-menopausal and not of child bearing potential.

          -  Mini-Mental State Examination (MMSE) total score ≥ 24 (at screening or in previous 3
             months) and cognitively unimpaired as evaluated by memory tests performed at
             screening.

          -  Homozygous APOE4 genotype.

          -  Participant's willingness to have a study partner.

        Exclusion Criteria:

          -  Any disability that may prevent the participants from completing all study
             requirements.

          -  Current medical or neurological condition that might impact cognition or performance
             on cognitive assessments.

          -  Advanced, severe progressive or unstable disease that may interfere with the safety,
             tolerability and study assessments, or put the participant at special risk.

          -  History of malignancy of any organ system, treated or untreated, within the past 60
             months.

          -  History of hypersensitivity to any of the investigational drugs or their excipients /
             adjuvant or to drugs of similar chemical classes.

          -  Indication for, or current treatment with ChEIs and/or another AD treatment (e.g.
             memantine).

          -  Contraindication or intolerance to MRI or PET investigations (with fluorinated radio
             ligands).

          -  Brain MRI results showing findings unrelated to AD that, in the opinion of the
             Investigator might be a leading cause to future cognitive decline, might pose a risk
             to the participant, or might prevent a satisfactory MRI assessment for safety
             monitoring.

          -  Suicidal Ideation in the past six months, or Suicidal Behavior in the past two years.

          -  A positive drug screen at Screening, if, in the Investigator's opinion, this is due to
             drug abuse.

          -  Significantly abnormal laboratory results at Screening, or infection not as a result
             of a temporary condition.

          -  Current clinically significant ECG findings. For Cohort - I only: Participants with
             previous organ transplantation or stem cell transplantation, or indication for
             treatment with anti-coagulants.

        For Cohort - II only: Participants with depigmenting or hypopigmenting conditions (e.g.
        albinism vitiligo) or active / history of chronic urticarial in the past year.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Novartis Pharmaceuticals</last_name>
    <phone>1-888-669-6682</phone>
    <email>trialandresults.registries@novartis.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Novartis Pharmaceuticals</last_name>
    <phone>+41613241111</phone>
    <email>info@generationprogram.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Banner Alzheimer's Institute</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85006</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>602-839-6500</phone>
      <email>roma.patel@bannerhealth.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic Arizona</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85259</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>480-301-6726</phone>
      <email>Thomas.martha1@mayo.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Banner Sun City Research Institute</name>
      <address>
        <city>Sun City</city>
        <state>Arizona</state>
        <zip>85351</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>623-832-6500</phone>
      <email>bannerresearch@bannerhealth.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>ATP Clinical Research, Inc.</name>
      <address>
        <city>Costa Mesa</city>
        <state>California</state>
        <zip>92626</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>714-277-4472</phone>
      <email>info@atpcr.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Irvine Center for Clinical Research</name>
      <address>
        <city>Irvine</city>
        <state>California</state>
        <zip>92614</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>949-753-1663</phone>
      <email>studies@irvineclinical.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92103</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Syrentis Clinical Research</name>
      <address>
        <city>Santa Ana</city>
        <state>California</state>
        <zip>92705</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>714-542-3008</phone>
      <email>lorriebisesiphd@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>California Neuroscience Research Medical Group, Inc.</name>
      <address>
        <city>Sherman Oaks</city>
        <state>California</state>
        <zip>91316</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>818-990-2671</phone>
      <email>marlene@cnrmg.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Temecula</city>
        <state>California</state>
        <zip>92591</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Yale University Alzheimer's Disease Research Unit</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06510</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>203-764-8100</phone>
      <email>Emily.kemp@yale.edu</email>
    </contact>
    <contact_backup>
      <phone>203-764-8145</phone>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>New England Institute for Clinical Research</name>
      <address>
        <city>Stamford</city>
        <state>Connecticut</state>
        <zip>06905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Haley Dunning</last_name>
      <phone>203-914-1903</phone>
      <email>haley@neinh.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Georgetown University</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20057</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>202-687-8800</phone>
      <email>mj582@georgetown.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>JEM Research Institute</name>
      <address>
        <city>Atlantis</city>
        <state>Florida</state>
        <zip>33462-6608</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>561-968-2933</phone>
      <email>mdaggerhart@jemri.net</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Florida Atlantic University, Clinical Translational Research Unit</name>
      <address>
        <city>Boca Raton</city>
        <state>Florida</state>
        <zip>33431</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>561-297-0164</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Brain Matters Research</name>
      <address>
        <city>Delray Beach</city>
        <state>Florida</state>
        <zip>33445</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>561-381-9060</phone>
      <email>jlesmes@brainmattersresearch.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic Jacksonville</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32224</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>904-953-8014</phone>
      <email>Walkermoore.kimpoki@mayo.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Meridien Research</name>
      <address>
        <city>Maitland</city>
        <state>Florida</state>
        <zip>32751</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>407-644-1165</phone>
      <email>emackey@meridienresearch.net</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Merritt Island Medical Research</name>
      <address>
        <city>Merritt Island</city>
        <state>Florida</state>
        <zip>32952</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>321-305-5015</phone>
      <email>info@mimresearch.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Miami Beach</city>
        <state>Florida</state>
        <zip>33140</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Miami</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>305-355-9120</phone>
      <email>brobertson@med.miami.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Compass Research</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32812</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>407-210-1337</phone>
      <email>Jennifer.Trotter@Compass.Bioclinica.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Port Orange</city>
        <state>Florida</state>
        <zip>32127</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>USF Health Byrd Alzheimer's Institute</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33613</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>813-974-9383</phone>
      <email>habulaban@health.usf.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Medical Research &amp; Health Education Foundation, Inc.</name>
      <address>
        <city>Columbus</city>
        <state>Georgia</state>
        <zip>31909</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>706-653-8455</phone>
      <email>Research4@stork.md</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>NeuroStudies</name>
      <address>
        <city>Decatur</city>
        <state>Georgia</state>
        <zip>30033</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>404-475-0552</phone>
      <email>jcavin@neurostudies.net</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Advanced Clinical Research</name>
      <address>
        <city>Meridian</city>
        <state>Idaho</state>
        <zip>83642</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>208-377-8653</phone>
      <email>kdellergo@acr-research.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Rush University Medical Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>312-942-0050</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Great Lakes Clinical Trials</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60640</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>773-275-3500</phone>
      <email>info@greatlakesclinicaltrials.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Indiana University</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>317-963-7440</phone>
      <email>aklaehn@iupui.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Kansas Alzheimer's Disease Center</name>
      <address>
        <city>Fairway</city>
        <state>Kansas</state>
        <zip>66205</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>913-588-0555</phone>
      <email>kuamp@kumc.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Via Christi Research</name>
      <address>
        <city>Wichita</city>
        <state>Kansas</state>
        <zip>67214</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>316-291-4673</phone>
      <email>Janie.krull@ascension.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sanders Brown Center on Aging, University of Kentucky</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40504</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>859-323-1331</phone>
      <email>shbardach@uky.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Brigham &amp; Women's Hospital Center for Alzheimer Research and Treatment</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>01801</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>617-525-8383</phone>
      <email>mvandervliet@partners.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55902</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Memory Disorders Program, Department of Neurological Sciences, University of Nebraska Medical Center</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68198-7680</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>402-552-6233</phone>
      <email>rhogue@unmc.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic Lou Ruvo Center for Brain Health</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89106</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>702-483-6026</phone>
      <email>brainhealth@ccf.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Memory Enhancement Center</name>
      <address>
        <city>Eatontown</city>
        <state>New Jersey</state>
        <zip>07724</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>732-263-0101</phone>
      <email>Mornstein@memorycenternj.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The memory Center of Northeastern New York</name>
      <address>
        <city>Latham</city>
        <state>New York</state>
        <zip>12110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>518-785-1000</phone>
      <email>cfrazier@tristateneuro.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>NYU Langone Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>212-263-5845</phone>
      <email>Mrunalini.gaikwad@nyumc.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Nathan S. Kline Institute</name>
      <address>
        <city>Orangeburg</city>
        <state>New York</state>
        <zip>10962</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>845-398-5582</phone>
      <email>Sameh.Nosir@nki.rfmh.org</email>
    </contact>
    <contact_backup>
      <phone>845-398-6532</phone>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>University of Rochester Medical Center</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14620</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>585-760-6562</phone>
      <email>Susan_salem-spencer@urmc.rochester.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Alzheimer's Memory Center</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28270</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>704-364-4000</phone>
      <phone_ext>235</phone_ext>
      <email>hswierc@amcneurology.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Duke University Medical center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27705</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>919-668-2841</phone>
      <email>Jessica.carlson@duke.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Triad Clinical Trials, LLC</name>
      <address>
        <city>Greensboro</city>
        <state>North Carolina</state>
        <zip>27410</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>336-235-0991</phone>
      <email>Scott_whitt@triad.twcbc.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospitals Cleveland Medical Center / Case Western Reserve University</name>
      <address>
        <city>Beachwood</city>
        <state>Ohio</state>
        <zip>44122</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>216-464-6474</phone>
      <email>parrianne.fatica@uhhospitals.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>IPS Research Company</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73103</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>405-235-8188</phone>
      <email>sbrand@ipsresearch.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73112</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Memory Health Center at Summit Research Network</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>503-228-2273</phone>
      <email>oregon@summitnetwork.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Clinical Trial Center, LLC</name>
      <address>
        <city>Jenkintown</city>
        <state>Pennsylvania</state>
        <zip>19046</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>215-884-1700</phone>
      <email>alketa@theclinicaltrialcenter.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Abington Neurological Associates</name>
      <address>
        <city>Willow Grove</city>
        <state>Pennsylvania</state>
        <zip>19090</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>215-957-9250</phone>
      <email>denisegallagher.ana@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Butler Hospital Memory and Aging Program</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <zip>02906</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>401-455-6402</phone>
      <email>memory@butler.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Roper St. Francis - CBRI</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29401</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>843-724-2302</phone>
      <email>Allison.lapp@rsfh.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Knoxville</city>
        <state>Tennessee</state>
        <zip>37920</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>CNS Healthcare</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38119</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>901-843-1045</phone>
      <email>meminfo@cnshealthcare.com</email>
    </contact>
    <contact_backup>
      <phone>877-267-2122</phone>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Senior Adults Specialty Research</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78757</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>512-407-8628</phone>
      <email>mdraper@senioradults.net</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77054</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinical Trial Network</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77074</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>713-484-6947</phone>
      <email>mespiritu@ctntexas.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Memory Clinic</name>
      <address>
        <city>Bennington</city>
        <state>Vermont</state>
        <zip>05201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>802-447-1409</phone>
      <email>megan@memorydoc.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Spokane</city>
        <state>Washington</state>
        <zip>99204</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Universal Research Group</name>
      <address>
        <city>Tacoma</city>
        <state>Washington</state>
        <zip>98405</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>253-882-1070</phone>
      <email>Info.uniresearch@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Medical College of WI</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>414-805-8328</phone>
      <email>bblaney@mcw.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Okanagan Clinical Trials</name>
      <address>
        <city>Kelowna</city>
        <state>British Columbia</state>
        <zip>V1Y1Z9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>250-862-8141</phone>
      <email>drchristie@oktrials.ca</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Toronto Memory Program</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M3B 2S7</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>416-386-9606</phone>
      <email>research@memorydisorders.ca</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Centre for Memory and Aging</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M4G 3E8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>416-663-6897</phone>
      <phone_ext>23</phone_ext>
      <email>lcornejo@memorycentre.ca</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Q&amp;T Research Sherbrooke</name>
      <address>
        <city>Sherbrooke</city>
        <state>Quebec</state>
        <zip>J1J 2G2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>819-562-6374</phone>
      <email>pierre.gervais@qtresearch.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Turku</city>
        <zip>20520</zip>
        <country>Finland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Amsterdam</city>
        <zip>1081 GN</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Barcelona</city>
        <zip>08005</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Basel</city>
        <state>CH</state>
        <zip>4002</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Lausanne</city>
        <zip>CH-1011</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Westbruy On Trym</city>
        <state>Bristol</state>
        <zip>BS10 5NB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Avon</city>
        <zip>BA1 3NG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Glasgow</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>London</city>
        <zip>W2 1PG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Canada</country>
    <country>Finland</country>
    <country>Netherlands</country>
    <country>Spain</country>
    <country>Switzerland</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.generationprogram.com</url>
    <description>Generation Program web site</description>
  </link>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 28, 2015</study_first_submitted>
  <study_first_submitted_qc>September 29, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 1, 2015</study_first_posted>
  <last_update_submitted>May 4, 2018</last_update_submitted>
  <last_update_submitted_qc>May 4, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 7, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Randomization, Placebo controlled, Parallel-group, APOE4 Homozygotes, Preclinical Alzheimer's Disease (AD), Aβ lowering</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.
This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

